Key points
- Revenue up 18% to $60.3 million
- Net profit after tax $0.2 million
- EBITDA up 72% to $5.4 million
Full summary
Compumedics Ltd's FY26 Preliminary Final Report highlights a significant improvement in financial performance. The company reported a revenue increase of 18% to $60.3 million, driven by successful magnetoencephalography (MEG) system deliveries, growth in connected sleep platforms, and a more diversified revenue mix. The net profit after tax was $0.2 million, compared to a loss of $1.3 million in FY25. EBITDA increased by 72% to $5.4 million, reflecting higher shipped and invoiced revenue, cost savings, and higher other income. The company also noted strong growth in Asia Pacific, partly offset by lower capital equipment invoicing in the Americas and Europe.
Guidance
FY26 revenue $60.3 million, net profit $0.2 million, EBITDA $5.4 million
Outlook
Compumedics Ltd remains focused on improving capital equipment conversion and margin performance, with a strategic emphasis on the fast-growing sleep diagnostics market and neuro-diagnostics.